Twist Bioscience Co. (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has received an average rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $51.90.

A number of equities research analysts recently commented on TWST shares. TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird boosted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Barclays reduced their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company.

Insider Buying and Selling

In related news, insider Dennis Cho sold 659 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now directly owns 94,481 shares in the company, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Chess sold 3,504 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $51.85, for a total value of $181,682.40. Following the completion of the sale, the director now owns 21,641 shares in the company, valued at $1,122,085.85. The trade was a 13.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 78,754 shares of company stock worth $3,619,144 over the last ninety days. Company insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience in the third quarter valued at $34,000. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience in the 2nd quarter valued at about $61,000. Beaird Harris Wealth Management LLC acquired a new position in shares of Twist Bioscience during the 3rd quarter worth about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Twist Bioscience Stock Performance

TWST opened at $45.62 on Wednesday. The company has a fifty day moving average price of $46.22 and a two-hundred day moving average price of $46.48. The firm has a market capitalization of $2.71 billion, a PE ratio of -12.67 and a beta of 1.85. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.